Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 29.06.2026 1 Ann Oncol 1 Ann Surg Oncol 7 Ann Thorac Surg 1 Arch Bronconeumol 1 Arch Pathol Lab Med 18 BMC Cancer 1 Br J Cancer 1 Cancer Chemother Pharmacol 1 Cancer Res 1 Clin Cancer Res 1 Clin Exp Metastasis 1 Clin Lung Cancer 2 Eur J Cancer 1 Eur J Cardiothorac Surg 1 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 2 Lung Cancer 1 Nat Med 3 Oncogene 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. ALDEA M, Lenahan SM, Locquet MA, Liao L, et al
   MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.
   Ann Oncol. 2026;37:946-959.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. TANE S, Nomura K, Watanabe T, Takamori S, et al
   ASO Visual Abstract: Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2026 Jun 20. doi: 10.1245/s10434-026-20001.
   PubMed        
   
   

   
   Ann Thorac Surg

3. HOODA Z, Ries S, McCracken A, Carbone G, et al
   Outcomes of Lobectomy Versus Sublobar Resection for Clinical Stage IA3 Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2026 Jun 22:S0003-4975(26)00581.
   PubMed         Abstract available
   
   
4. KHULLAR OV, Kidane B, Altorki N, Antonoff M, et al
   STS Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-small Cell Lung Cancer.
   Ann Thorac Surg. 2026 Jun 19:S0003-4975(26)00579.
   PubMed         Abstract available
   
   
5. VELOTTA JB, Roden AC, Rice J, Simone CB, et al
   The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.
   Ann Thorac Surg. 2026;122:3-21.
   PubMed         Abstract available
   
   
6. LI H, Pezeshkian F, Sugarbaker E, Mazzola E, et al
   Optimal Margin for Sublobar Resection of Invasive Lung Adenocarcinoma Presenting as Mixed Ground-Glass Nodules.
   Ann Thorac Surg. 2026;122:159-168.
   PubMed         Abstract available
   
   
7. XU J, Wang K, Zhang G, Liu X, et al
   Surgical and Survival Benefits of Neoadjuvant Targeted Therapy vs Chemoimmunotherapy in Lung Adenocarcinoma: A Dual-Center Research.
   Ann Thorac Surg. 2026;122:170-177.
   PubMed         Abstract available
   
   
8. GULATI S, Wolf A, Mehrotra-Varma J, Tuminello S, et al
   Disaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma.
   Ann Thorac Surg. 2026;122:178-185.
   PubMed         Abstract available
   
   
9. COWAN BE, Xiao M, Gomes C, Laxmanan B, et al
   Atypical Histology in Pulmonary Biopsies Obtained Using Robotic-Assisted Bronchoscopy: Natural History and Clinical Practice.
   Ann Thorac Surg. 2026;122:186-193.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

10. SONG Q, Shang S, Zhai Z, Ma S, et al
    Circulating Tumor DNA is Associated With Pathologic Response and Survival Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy: A Systematic Review and Meta-Analysis.
    Arch Bronconeumol. 2026 Jun 4:S0300-2896(26)00212.
    PubMed         Abstract available
    
    

    
    Arch Pathol Lab Med

11. TAWFIK OW, Smith R, Thomason J, Aboudara M, et al
    Retrospective Comparison of Operational Metrics Across Diagnostic Approaches for Molecular Testing in Lung and Colon Cancers in a Community-Based Setting.
    Arch Pathol Lab Med. 2026;150:513-519.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. WU J, Zhang L, Zhang Z, Gao S, et al
    Using machine learning algorithms based on laboratory indicators to establish a diagnostic model for lung cancer.
    BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16239.
    PubMed         Abstract available
    
    
13. AKKURT ES, Duvenci Birben O, Deliktas Onur I, Dagli D, et al
    Determinants of severity in immune checkpoint inhibitor-related pneumonitis: clinical, radiologic, and laboratory insights from real-life clinical data.
    BMC Cancer. 2026;26:243.
    PubMed         Abstract available
    
    
14. LIU X, Li S, Zhou M, Ding N, et al
    M6A modification-related genes characterize prognostic risk and immune regulation in lung adenocarcinoma.
    BMC Cancer. 2026;26:226.
    PubMed         Abstract available
    
    
15. SHI W, Hu Y, Chang G, Yang Y, et al
    Development and validation of a nomogram for preoperative prediction of the invasiveness of stage T1 lung adenocarcinoma utilizing AI-driven radiomics.
    BMC Cancer. 2026;26:199.
    PubMed         Abstract available
    
    
16. LI J, Yang Z, Liu L, Tang F, et al
    Predicting PD-L1 expression in advanced EGFR-mutant lung adenocarcinoma patients using NECT, CECT radiomics and clinical features.
    BMC Cancer. 2026;26:178.
    PubMed         Abstract available
    
    
17. YANG Y, Kong S, Hei Y, Yang R, et al
    Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study.
    BMC Cancer. 2025;26:136.
    PubMed         Abstract available
    
    
18. ZHOU S, Gao M, Dong S, Wang M, et al
    Identification and functional characterization of genes associated with lipopolysaccharide in lung adenocarcinoma.
    BMC Cancer. 2025;26:54.
    PubMed         Abstract available
    
    
19. WANG Y, Yu F, Qiu F, Fang K, et al
    Global burden of respiratory system cancers in 2022 and 2050: incidence and mortality estimates from GLOBOCAN.
    BMC Cancer. 2025;25:1832.
    PubMed         Abstract available
    
    
20. SHI J, Wang Y, Pang J, Yin JC, et al
    Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study.
    BMC Cancer. 2025;26:18.
    PubMed         Abstract available
    
    
21. MIN W, He D, Liu X, Zhu X, et al
    Proteomics of malignant pleural mesothelioma under hypoxic and normoxic conditions in a large animal (porcine) tumor model.
    BMC Cancer. 2025;26:52.
    PubMed         Abstract available
    
    
22. LYU Q, Yuan H, Lin Z, Barcus R, et al
    A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type.
    BMC Cancer. 2025;25:1821.
    PubMed         Abstract available
    
    
23. YANG X, Gao S, Ju R, Ji X, et al
    Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.
    BMC Cancer. 2025;25:1765.
    PubMed         Abstract available
    
    
24. LIN M, Zhao C, Huang H, Zhao X, et al
    The clinical value of predicting lymphovascular invasion in patients with invasive lung adenocarcinoma based on the intratumoral and peritumoral CT radiomics models.
    BMC Cancer. 2025;25:1752.
    PubMed         Abstract available
    
    
25. LU Z, Bao P, Wang T, Hu K, et al
    Multi-omics data-based modeling reveals tumorigenesis- and prognosis-associated genes with clinical potential in lung adenocarcinoma.
    BMC Cancer. 2025;25:1743.
    PubMed         Abstract available
    
    
26. LIN M, Li L, Hui Y, Li B, et al
    Machine learning-based prediction of invasiveness in lung adenocarcinoma presenting as ground-glass nodules using radiomics and clinical CT features.
    BMC Cancer. 2025;25:1693.
    PubMed         Abstract available
    
    
27. YANG Y, Jiang HY, Li Y, Wu F, et al
    Pre-treatment peripheral blood TCR repertoire as a predictor of response in patients with NSCLC treated with immunochemotherapy.
    BMC Cancer. 2025;25:1105.
    PubMed         Abstract available
    
    
28. HUANG TT, Wang XY, Li Q, Song PF, et al
    Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study.
    BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16412.
    PubMed         Abstract available
    
    
29. QIU J, Yue H, Wang S, Li K, et al
    Distribution and rate of lymph node metastasis following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
    BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16407.
    PubMed         Abstract available
    
    

    
    Br J Cancer

30. LIU C, Fukuda E, Sagiya Y, Tsuru H, et al
    Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma.
    Br J Cancer. 2026 Jun 25. doi: 10.1038/s41416-026-03504.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

31. GRACIA M, Marsili S, Vintejoux J, Gladieff L, et al
    Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy.
    Cancer Chemother Pharmacol. 2025;95:124.
    PubMed         Abstract available
    
    

    
    Cancer Res

32. CLARKE MA, Barker CG, Nicholls A, Handler MP, et al
    Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.
    Cancer Res. 2026 Jun 24. doi: 10.1158/0008-5472.CAN-25-2476.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

33. BORGHAEI H, Balli D, Paz-Ares LG, Reck M, et al
    Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jun 26:OF1-OF14. doi: 10.1158/1078-0432.CCR-25-0942.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

34. DENG G, Zhou Y, Wang Z, Fan J, et al
    Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs.
    Clin Exp Metastasis. 2025;42:51.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

35. LU K, Patel SP, Azenkot T
    Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report.
    Clin Lung Cancer. 2026;27:64-67.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

36. MATSUMOTO K, Yamamoto Y, Shiroyama T, Kuge T, et al
    Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.
    Eur J Cancer. 2026;244:116902.
    PubMed         Abstract available
    
    
37. FU Y, Kong R, Liang W
    Letter to the editor Re: Patient-reported outcomes from the LAURA study: Osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
    Eur J Cancer. 2026;244:116891.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

38. ONODERA K, Aokage K, Saji H, Wakabayashi M, et al
    Oncologic Safety of Omitting Mediastinal Lymph Node Dissection in Segmentectomy for Ground-Glass Opacity-Dominant Lung Cancer: A Supplementary Analysis of JCOG1211.
    Eur J Cardiothorac Surg. 2026;68:ezag184.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

39. MILGROM SA, Paganetti H, Dama H, Renfro L, et al
    Subsequent Neoplasm Risk after Modern Mediastinal Radiotherapy for Pediatric Hodgkin Lymphoma: Insights from a Multi-Institutional Children's Oncology Group Trial.
    Int J Radiat Oncol Biol Phys. 2026 Feb 6:S0360-3016(26)00361.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

40. MEHRI-KAKAVAND G, Mdletshe S, Amini M, Wang A, et al
    Multimodal radiomics fusion for predicting postoperative recurrence in NSCLC patients.
    J Cancer Res Clin Oncol. 2025;151:261.
    PubMed         Abstract available
    
    
41. PARKER RE, McSwain L, Zhou W, Marcus AI, et al
    High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2025;151:223.
    PubMed         Abstract available
    
    

    
    Lung Cancer

42. CHEN L, Feng Y, Liu M, Abulizi D, et al
    Dietary inflammatory index and lung cancer risk: multi-cohort evidence and plasma proteomic profiles.
    Lung Cancer. 2026;218:109505.
    PubMed         Abstract available
    
    
43. TEMPLEMENT-GRANGERAT D, Locher C, Neidhardt AC, Fore M, et al
    Sex disparities in lung cancer: Results of the KBP-2020-CPHG study.
    Lung Cancer. 2026;218:109503.
    PubMed         Abstract available
    
    

    
    Nat Med

44. HUANG Z, Zeng L, Ruan Z, Zeng Q, et al
    Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2026 Jun 24. doi: 10.1038/s41591-026-04508.
    PubMed        
    
    

    
    Oncogene

45. HUANG H, Ding C, Zhao Z, Zhao W, et al
    Hypoxia-induced MIC19 myristoylation promotes PRKN-dependent VDAC2 ubiquitination and activates mitophagy in non-small cell lung cancer.
    Oncogene. 2026 Jun 20. doi: 10.1038/s41388-026-03847.
    PubMed         Abstract available
    
    
46. ZHANG M, Hu C, Liu H, Zhang C, et al
    MST4 plays dual roles in lung adenocarcinoma by regulating homeostasis of wild-type and mutant p53 protein.
    Oncogene. 2026;45:2567-2578.
    PubMed         Abstract available
    
    
47. CAO Y, Wei J, Chen Q, Wang H, et al
    Liver-specific SIRT1 knockout-induced hyperglycemia promotes spontaneous lung adenocarcinomas through HSF1-MDM2.
    Oncogene. 2026;45:2537-2551.
    PubMed         Abstract available
    
    

    
    PLoS One

48. LO SASSO A, Amoroso N, Diacono D, La Rocca M, et al
    Enhancing breath-based diagnostics through eXplainable Artificial Intelligence.
    PLoS One. 2026;21:e0351833.
    PubMed         Abstract available
    
    
49. YUAN Q, Zhang D, Xu R, Yao W, et al
    Adenosquamous carcinoma of the lung: Comparative CT and pathological features versus adenocarcinoma and squamous cell carcinoma.
    PLoS One. 2026;21:e0352454.
    PubMed         Abstract available
    
    
50. FORERO YJ, Kammer MN, McGann KC, Holmes H, et al
    Longitudinal analysis of CYFRA 21-1 levels in patients with pulmonary nodules: Differential trajectories between benign and malignant cases.
    PLoS One. 2026;21:e0341522.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

51. LI G, Li Q, Zhang J, Huang Y, et al
    p53 overrides METTL5 loss-induced tumor suppression via mitochondrial respiration.
    Proc Natl Acad Sci U S A. 2026;123:e2604695123.
    PubMed         Abstract available
    
    

    
    Thorax

52. ZHANG Y, Hinde S, Marshall CS, Hancock N, et al
    Comparative cost-effectiveness of screening for lung cancer using different risk scores and thresholds: the Yorkshire Lung Screening Trial.
    Thorax. 2026 Jun 25:thorax-2025-223859. doi: 10.1136/thorax-2025-223859.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum